Summary

Acute kidney injury (AKI) is a major complication of cardiac surgery and can progress to chronic kidney disease and death. Allogeneic mesenchymal stem cells (MSCs) have been shown to reduce the severity of and improve the recovery from AKI in preclinical studies. This article discusses A Study to Evaluate the Safety and Efficacy of AC607 for the Treatment of Kidney Injury in Cardiac Surgery Subjects [NCT01602328], which compared the time to kidney recovery with AC607 vs placebo in the setting of postcardiac surgery.